News Posts List
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
03/23/2010
Cancer immunotherapy involving natural killer (NK) cell infusions and administration of therapeutic agents modulating the susceptibility of tumors to NK-cell lysis has been proposed recently.
KCA Recognized by ASCO Cancer Foundation®
03/22/2010
List of Foundations and Non-Profit Organizations
Ambitious climb honors dad who suffered from kidney cancer
03/22/2010
"It's called Kidney Klimb. We hope to raise $10,000 for kidney cancer awareness and for families in the area who are dealing with this. The bulk of our money will go to families, but we will give some to the Kidney Cancer Association..."
Former PR exec for Disney and Irvine Co. dies
03/22/2010
C. Thomas Wilck, 75, died July 24 from kidney cancer.
Laparoscopic Radical Nephrectomy For Renal Cell Carcinoma
03/21/2010
In 73 patients with kidney cancer undergoing laparoscopic radical nephrectomy and followed for mean 11.2 years, cancer-specific and overall survival were 78% and 35%, respectively. Cancer recurred in 11% of patients; in 7%, the recurrence occurred late at 8-10 years after surgery.
Loss of expression of TIMP3 in clear cell renal cell carcinoma
03/21/2010
In clear cell renal cell carcinoma (CCRCC), vascular endothelial growth factor (VEGF) represents the central positive mediator of tumour angiogenesis while VEGF receptor (VEGFR) is the primary target of anti-angiogenic therapies. TIMP3 is a physiological VEGFR-2 antagonist and thus could be considered as an anti-angiogenic factor. We therefore determined the status of this physiological inhibitor in CCRCC.
UK cancer death risk is 70% higher in men
03/20/2010
Unhealthy lifestyles and a 'stiff upper lip' make men up to 70 per cent more likely to die from cancer than women, doctors have warned.
Roche Increased Avastin Sales Efforts; Doubles US Force
03/20/2010
The moves come after Roche paid $46.8 billion to takeover Genentech Inc., which developed the drug. Avastin was Roche's biggest seller in 2009 with sales of about $5.9 billion, making up about 13% of its total, but it has faced multiple setbacks in its development since the deal closed about a year ago.
Orangeburg man runs marathon to raise $50K for KCA
03/19/2010
He plans to run in the New York City Half-Marathon on March 21. He hopes to raise $50,000 for the Kidney Cancer Association.
News Feed